» Articles » PMID: 22561420

Resistance of Colon Cancer to 5-fluorouracil May Be Overcome by Combination with Chloroquine, an in Vivo Study

Overview
Specialty Oncology
Date 2012 May 8
PMID 22561420
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Autophagy is a complex of adaptive cellular response that enhances cancer cell survival in the face of cellular stresses such as chemotherapy. Recently, chloroquine diphosphate (CQ), a widely used antimalarial drug, has been studied as a potential inhibitor of autophagy. Here, we aimed to investigate the role of CQ in potentiating the effect of 5-fluorouracil (5-FU), the chemotherapeutic agent of first choice for the treatment of colorectal cancer, in an animal model of colon cancer. The mouse colon cancer cell line colon26 was used. For the in-vivo study, colon26 cells were injected subcutaneously into BALB/c mice, which were treated with saline as a control, CQ (50 mg/kg/day), 5-FU (30 mg/kg/day), or the combination therapy (CQ plus 5-FU). The tumor volume ratio and body weight were monitored. After the sacrifice, tumor tissue protein extracts and tumor sections were prepared and subjected to immunoblotting for the analysis of autophagy-related and apoptosis-related proteins, and the terminal transferase uridyl end labeling assay. The combination of CQ resulted in the inhibition of 5-FU-induced autophagy and a significant enhancement in the 5-FU-induced inhibition of tumor growth. Furthermore, the combination treatment of CQ and 5-FU resulted in a significant increase in the ratio of apoptotic cells compared with other treatments. The expression levels of the proapoptotic proteins, namely Bad and Bax, were increased by the CQ treatment in the protein extracts from tumors. Our findings suggest that the combination therapy of CQ and 5-FU should be considered as an effective strategy for the treatment of colorectal cancer.

Citing Articles

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.

Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).

PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.


Colorectal cancer: Recent advances in management and treatment.

Fadlallah H, El Masri J, Fakhereddine H, Youssef J, Chemaly C, Doughan S World J Clin Oncol. 2024; 15(9):1136-1156.

PMID: 39351451 PMC: 11438855. DOI: 10.5306/wjco.v15.i9.1136.


Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions.

Yan L, Shi J, Zhu J Discov Oncol. 2024; 15(1):294.

PMID: 39031216 PMC: 11265098. DOI: 10.1007/s12672-024-01163-1.


CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34.

Huang Z, Kaller M, Hermeking H Cell Death Differ. 2023; 30(8):2017-2034.

PMID: 37488217 PMC: 10406948. DOI: 10.1038/s41418-023-01193-2.


Regulation of 5-fluorodeoxyuridine monophosphate-thymidylate synthase ternary complex levels by autophagy confers resistance to 5-fluorouracil.

Nishizawa N, Kurasaka C, Ogino Y, Sato A FASEB Bioadv. 2023; 5(1):43-51.

PMID: 36643896 PMC: 9832531. DOI: 10.1096/fba.2022-00099.